• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

今天和明天的卵巢癌:基于 GLOBOCAN 2020 的全球按世界区域和人类发展指数评估。

Ovarian cancer today and tomorrow: A global assessment by world region and Human Development Index using GLOBOCAN 2020.

机构信息

Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France.

The Royal Marsden NHS Foundation Trust, London, UK.

出版信息

Int J Cancer. 2022 Nov 1;151(9):1535-1541. doi: 10.1002/ijc.34002. Epub 2022 Mar 30.

DOI:10.1002/ijc.34002
PMID:35322413
Abstract

Ovarian cancer remains to have relatively poor prognosis particularly in low-resourced settings. It is therefore important to continually examine the burden of ovarian cancer to identify areas of disparities. Our study aims to provide an overview of the global burden of ovarian cancer using the GLOBOCAN 2020 estimates by country, world region, and Human Development Index (HDI) levels, as well as the predicted future burden by the year 2040 by HDI. Age-standardized incidence and mortality rates for ovarian cancer in 185 countries were calculated by country, world region, and for the four-tier HDI. The number of new cases and deaths were projected for the year 2040 based on demographic projections by HDI category. Approximately 314 000 new ovarian cancer cases and 207 000 deaths occurred in 2020. There were marked geographic variations in incidence rates, with the highest rates observed in European countries with very high HDI and low rates were found in African countries within the lowest HDI group. Comparable mortality rates were observed across the four-tier HDI. Relative to 2020 estimates, our projection for 2040 indicates approximately 96% and 100% increase in new ovarian cancer cases and deaths, respectively, among low HDI countries compared to 19% and 28% in very high HDI countries. Our study highlights the disproportionate current and future burden of ovarian cancer in countries with lower HDI levels, calling for global action to reduce the burden and inequality of ovarian cancer in access to quality cancer care and treatment.

摘要

卵巢癌的预后仍然较差,特别是在资源匮乏的环境中。因此,不断检查卵巢癌的负担,以确定差距领域非常重要。我们的研究旨在利用 GLOBOCAN 2020 按国家、世界区域和人类发展指数 (HDI) 水平估算的结果,以及按 HDI 预测的 2040 年未来负担,概述全球卵巢癌负担。按国家、世界区域和四层次 HDI 计算了 185 个国家的卵巢癌年龄标准化发病率和死亡率。根据 HDI 类别预测的人口预测,预计 2040 年的新发病例和死亡人数。2020 年,约有 314000 例新卵巢癌病例和 207000 例死亡。发病率存在明显的地域差异,发病率最高的是人类发展指数非常高的欧洲国家,而发病率最低的是人类发展指数最低组的非洲国家。在四层次的 HDI 中,死亡率相当。与 2020 年的估计相比,我们对 2040 年的预测显示,与人类发展指数非常高的国家相比,低人类发展指数国家的新卵巢癌病例和死亡人数分别增加了约 96%和 100%,而高人类发展指数国家的病例和死亡人数分别增加了 19%和 28%。我们的研究强调了低 HDI 国家当前和未来卵巢癌负担不成比例的问题,呼吁采取全球行动,以减少全球卵巢癌负担和不平等现象,改善获得优质癌症护理和治疗的机会。

相似文献

1
Ovarian cancer today and tomorrow: A global assessment by world region and Human Development Index using GLOBOCAN 2020.今天和明天的卵巢癌:基于 GLOBOCAN 2020 的全球按世界区域和人类发展指数评估。
Int J Cancer. 2022 Nov 1;151(9):1535-1541. doi: 10.1002/ijc.34002. Epub 2022 Mar 30.
2
Global burden of gynaecological cancers in 2022 and projections to 2050.2022 年全球妇科癌症负担及 2050 年预测。
J Glob Health. 2024 Aug 16;14:04155. doi: 10.7189/jogh.14.04155.
3
Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative.2020 年全球宫颈癌发病率和死亡率估计:世卫组织全球消除宫颈癌倡议的基线分析。
Lancet Glob Health. 2023 Feb;11(2):e197-e206. doi: 10.1016/S2214-109X(22)00501-0. Epub 2022 Dec 14.
4
Global esophageal cancer epidemiology in 2022 and predictions for 2050: A comprehensive analysis and projections based on GLOBOCAN data.2022年全球食管癌流行病学及2050年预测:基于全球癌症数据库(GLOBOCAN)数据的综合分析与预测
Chin Med J (Engl). 2024 Dec 20;137(24):3108-3116. doi: 10.1097/CM9.0000000000003420. Epub 2024 Dec 13.
5
The current and future global burden of cancer among adolescents and young adults: a population-based study.青少年和青年人群中癌症的当前及未来全球负担:一项基于人群的研究。
Lancet Oncol. 2024 Dec;25(12):1614-1624. doi: 10.1016/S1470-2045(24)00523-0. Epub 2024 Nov 15.
6
Global burden of thyroid cancer in 2022: Incidence and mortality estimates from GLOBOCAN.2022 年全球甲状腺癌负担:基于 GLOBOCAN 的发病率和死亡率估计。
Chin Med J (Engl). 2024 Nov 5;137(21):2567-2576. doi: 10.1097/CM9.0000000000003284. Epub 2024 Sep 12.
7
Global cancer statistics for adolescents and young adults: population based study.全球青少年和青年癌症统计数据:基于人群的研究。
J Hematol Oncol. 2024 Oct 21;17(1):99. doi: 10.1186/s13045-024-01623-9.
8
Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN.2020年和2040年全球结直肠癌负担:来自全球癌症负担(GLOBOCAN)的发病率和死亡率估计
Gut. 2023 Feb;72(2):338-344. doi: 10.1136/gutjnl-2022-327736. Epub 2022 Sep 8.
9
The current and future incidence and mortality of gastric cancer in 185 countries, 2020-40: A population-based modelling study.2020 - 2040年185个国家胃癌的当前及未来发病率和死亡率:一项基于人群的建模研究
EClinicalMedicine. 2022 Apr 21;47:101404. doi: 10.1016/j.eclinm.2022.101404. eCollection 2022 May.
10
Global epidemiology of liver cancer 2022: An emphasis on geographic disparities.全球 2022 年肝癌流行病学:重点关注地理差异。
Chin Med J (Engl). 2024 Oct 5;137(19):2334-2342. doi: 10.1097/CM9.0000000000003264. Epub 2024 Sep 3.

引用本文的文献

1
Global determinants of gynecologic cancer incidence and mortality: A cluster-based analysis with predictive insights.妇科癌症发病率和死亡率的全球决定因素:基于聚类的分析及预测性见解。
Int J Gynaecol Obstet. 2025 Sep;171 Suppl 1:147-165. doi: 10.1002/ijgo.70279.
2
Long-term trends and projections of ovarian cancer burden in China (1990 to 2040): an age-period-cohort analysis based on GBD 2021 data.中国卵巢癌负担的长期趋势及预测(1990年至2040年):基于全球疾病负担研究(GBD)2021数据的年龄-时期-队列分析
Front Oncol. 2025 Aug 14;15:1652347. doi: 10.3389/fonc.2025.1652347. eCollection 2025.
3
Ex vivo 3D micro-tumour testing platform for predicting clinical response to platinum-based therapy in patients with high-grade serous ovarian cancer.
用于预测高级别浆液性卵巢癌患者对铂类疗法临床反应的体外3D微肿瘤检测平台
NPJ Precis Oncol. 2025 Aug 30;9(1):306. doi: 10.1038/s41698-025-01080-8.
4
Exhausted and Senescent CD4 T Cells in Peripheral Blood and Their Impact as a Biological Marker for the Diagnosis of Benign and Malignant Ovarian Tumors.外周血中耗竭和衰老的CD4 T细胞及其作为良性和恶性卵巢肿瘤诊断生物学标志物的影响
Diagnostics (Basel). 2025 Aug 12;15(16):2019. doi: 10.3390/diagnostics15162019.
5
Revolutionizing ovarian cancer treatment: cryptic antigens as the next breakthrough in immunotherapy.变革卵巢癌治疗:隐匿抗原成为免疫疗法的下一个突破点。
Ann Med Surg (Lond). 2025 May 20;87(7):4003-4004. doi: 10.1097/MS9.0000000000003372. eCollection 2025 Jul.
6
Future theranostic strategies: emerging ovarian cancer biomarkers to bridge the gap between diagnosis and treatment.未来的诊疗策略:新兴的卵巢癌生物标志物以弥合诊断与治疗之间的差距。
Front Drug Deliv. 2024 Feb 1;4:1339936. doi: 10.3389/fddev.2024.1339936. eCollection 2024.
7
Functional validation of somatic variability in and for prediction of platinum sensitivity and prognosis in epithelial ovarian carcinoma patients.用于预测上皮性卵巢癌患者铂敏感性和预后的KRAS和BRAF体细胞变异性的功能验证。
Cancer Biol Ther. 2025 Dec;26(1):2543105. doi: 10.1080/15384047.2025.2543105. Epub 2025 Aug 10.
8
Pre- and post-diagnosis dietary total antioxidant capacity and overall survival in patients with ovarian cancer: a prospective cohort study.卵巢癌患者诊断前后的膳食总抗氧化能力与总生存期:一项前瞻性队列研究
Nutr J. 2025 Aug 1;24(1):122. doi: 10.1186/s12937-025-01185-7.
9
Exploring causal relationships between brain imaging-derived phenotypes and ovarian cancer risk: a bidirectional Mendelian randomization.探索脑成像衍生表型与卵巢癌风险之间的因果关系:双向孟德尔随机化研究
J Ovarian Res. 2025 Aug 1;18(1):173. doi: 10.1186/s13048-025-01733-z.
10
Physical, Emotional, and Stress-Related Dynamics over Six Months in Newly Diagnosed Epithelial Ovarian Cancer Survivors.新诊断上皮性卵巢癌幸存者六个月内的身体、情绪及压力相关动态变化
J Clin Med. 2025 Jul 17;14(14):5087. doi: 10.3390/jcm14145087.